Cargando…
Potassium-competitive acid blockers, a new therapeutic class, and their role in acid-related diseases: a narrative review
INTRODUCTION: A new therapeutic class, potassium-competitive acid blockers (P-CABs), has emerged in Brazil to promote a superior antisecretory effect addressing the unmet needs related to acid-related disease management. Vonoprazan fumarate showed a good safety profile and was approved by the Brazil...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10050988/ https://www.ncbi.nlm.nih.gov/pubmed/37007753 http://dx.doi.org/10.5114/pg.2022.116673 |
Sumario: | INTRODUCTION: A new therapeutic class, potassium-competitive acid blockers (P-CABs), has emerged in Brazil to promote a superior antisecretory effect addressing the unmet needs related to acid-related disease management. Vonoprazan fumarate showed a good safety profile and was approved by the Brazilian regulatory agency – ANVISA. AIM: This narrative review was conducted to review the general concepts regarding P-CABs, focussing on vonoprazan fumarate. MATERIAL AND METHODS: A literature search was conducted through April–May 2021 using official databases with a combination of MeSH controlled vocabulary and text words. The authors selected articles that described pivotal and novel insights about P-CABs and vonoprazan fumarate. RESULTS: Vonoprazan is a drug of the P-CABs class newly approved for the management of acid-related diseases in Brazil. P-CABs achieve rapid, potent, and prolonged acid suppression (including night-time) and promise to address some unmet clinical needs in GERD. Furthermore, considering the difficulties encountered in attaining effective symptomatic control – particularly at night – using currently available PPIs, this new drug class is promising. CONCLUSIONS: This review brings important information about vonoprazan, a new therapeutic option in Brazil, which may be considered as a valuable tool for managing acid-related diseases. |
---|